Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Metabolically programmed iron chelators.

Bergeron RJ, Bharti N, McManis JS, Wiegand J.

Bioorg Med Chem. 2015 Sep 1;23(17):5954-71. doi: 10.1016/j.bmc.2015.06.059. Epub 2015 Jun 29.

2.

Desferrithiocin: a search for clinically effective iron chelators.

Bergeron RJ, Wiegand J, McManis JS, Bharti N.

J Med Chem. 2014 Nov 26;57(22):9259-91. doi: 10.1021/jm500828f. Epub 2014 Sep 10. Review.

3.

Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

Bergeron RJ, Wiegand J, Bharti N, McManis JS.

J Med Chem. 2012 Aug 23;55(16):7090-103. doi: 10.1021/jm300509y. Epub 2012 Aug 13.

4.

Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity.

Bergeron RJ, Wiegand J, Bharti N, McManis JS, Singh S.

Biometals. 2011 Apr;24(2):239-58. doi: 10.1007/s10534-010-9389-y. Epub 2010 Nov 20.

5.

The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Bergeron RJ, Bharti N, Wiegand J, McManis JS, Singh S, Abboud KA.

J Med Chem. 2010 Apr 8;53(7):2843-53. doi: 10.1021/jm9018146.

6.

Vibriobactin antibodies: a vaccine strategy.

Bergeron RJ, Bharti N, Singh S, McManis JS, Wiegand J, Green LG.

J Med Chem. 2009 Jun 25;52(12):3801-13. doi: 10.1021/jm900119q.

7.

Desferrithiocin analogues and nephrotoxicity.

Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S.

J Med Chem. 2008 Oct 9;51(19):5993-6004. doi: 10.1021/jm8003398. Epub 2008 Sep 13.

8.

Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.

Bergeron RJ, Wiegand J, McManis JS, Bharti N, Singh S.

J Med Chem. 2008 Jul 10;51(13):3913-23. doi: 10.1021/jm800154m. Epub 2008 Jun 6.

9.

The design, synthesis, and evaluation of organ-specific iron chelators.

Bergeron RJ, Wiegand J, McManis JS, Bharti N.

J Med Chem. 2006 Nov 30;49(24):7032-43.

10.

(S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.

Bergeron RJ, Wiegand J, McManis JS, Vinson JR, Yao H, Bharti N, Rocca JR.

J Med Chem. 2006 May 4;49(9):2772-83.

11.

Polyamine-vectored iron chelators: the role of charge.

Bergeron RJ, Bharti N, Wiegand J, McManis JS, Yao H, Prokai L.

J Med Chem. 2005 Jun 16;48(12):4120-37.

PMID:
15943485
12.

Synthesis and biological evaluation of aminopolyamines.

Bergeron RJ, Huang G, McManis JS, Yao H, Nguyen JN.

J Med Chem. 2005 May 5;48(9):3099-102.

PMID:
15857111
13.

Partition-variant desferrithiocin analogues: organ targeting and increased iron clearance.

Bergeron RJ, Wiegand J, McManis JS, Weimar WR, Park JH, Eiler-McManis E, Bergeron J, Brittenham GM.

J Med Chem. 2005 Feb 10;48(3):821-31.

PMID:
15689166
14.

Polyamine-iron chelator conjugate.

Bergeron RJ, McManis JS, Franklin AM, Yao H, Weimar WR.

J Med Chem. 2003 Dec 4;46(25):5478-83.

PMID:
14640556
15.

Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.

Bergeron RJ, Wiegand J, Weimar WR, McManis JS, Smith RE, Abboud KA.

Chirality. 2003 Aug;15(7):593-9.

PMID:
12840823
16.

Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.

Bergeron RJ, Wiegand J, McManis JS, Bussenius J, Smith RE, Weimar WR.

J Med Chem. 2003 Apr 10;46(8):1470-7.

PMID:
12672247
17.

Structure-activity relationships among desazadesferrithiocin analogues.

Bergeron RJ, Wiegand J, McManis JS, Weimar WR, Huang G.

Adv Exp Med Biol. 2002;509:167-84. Review.

PMID:
12572994
18.

Desferrithiocin analogue based hexacoordinate iron(III) chelators.

Bergeron RJ, Huang G, Weimar WR, Smith RE, Wiegand J, McManis JS.

J Med Chem. 2003 Jan 2;46(1):16-24.

PMID:
12502356
19.

Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.

Bergeron RJ, Müller R, Huang G, McManis JS, Algee SE, Yao H, Weimar WR, Wiegand J.

J Med Chem. 2001 Jul 19;44(15):2451-9.

PMID:
11448227
20.

Polyamine analogue antidiarrheals: a structure-activity study.

Bergeron RJ, Wiegand J, McManis JS, Weimar WR, Smith RE, Algee SE, Fannin TL, Slusher MA, Snyder PS.

J Med Chem. 2001 Jan 18;44(2):232-44.

PMID:
11170633
21.

Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives.

Bergeron RJ, Müller R, Bussenius J, McManis JS, Merriman RL, Smith RE, Yao H, Weimar WR.

J Med Chem. 2000 Jan 27;43(2):224-35.

PMID:
10649978
22.

Evaluation of the desferrithiocin pharmacophore as a vector for hydroxamates.

Bergeron RJ, McManis JS, Bussenius J, Brittenham GM, Wiegand J.

J Med Chem. 1999 Jul 29;42(15):2881-6.

PMID:
10425097
23.

Effects of C-4 stereochemistry and C-4' hydroxylation on the iron clearing efficiency and toxicity of desferrithiocin analogues.

Bergeron RJ, Wiegand J, McManis JS, McCosar BH, Weimar WR, Brittenham GM, Smith RE.

J Med Chem. 1999 Jul 1;42(13):2432-40.

PMID:
10395484
24.

Desazadesmethyldesferrithiocin analogues as orally effective iron chelators.

Bergeron RJ, Wiegand J, Weimar WR, Vinson JR, Bussenius J, Yao GW, McManis JS.

J Med Chem. 1999 Jan 14;42(1):95-108.

PMID:
9888836
25.

Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells.

Kramer DL, Fogel-Petrovic M, Diegelman P, Cooley JM, Bernacki RJ, McManis JS, Bergeron RJ, Porter CW.

Cancer Res. 1997 Dec 15;57(24):5521-7.

26.

Structural basis for differential induction of spermidine/spermine N1-acetyltransferase activity by novel spermine analogs.

Fogel-Petrovic M, Kramer DL, Vujcic S, Miller J, McManis JS, Bergeron RJ, Porter CW.

Mol Pharmacol. 1997 Jul;52(1):69-74.

PMID:
9224814
27.

A comparison of structure-activity relationships between spermidine and spermine analogue antineoplastics.

Bergeron RJ, Feng Y, Weimar WR, McManis JS, Dimova H, Porter C, Raisler B, Phanstiel O.

J Med Chem. 1997 May 9;40(10):1475-94.

PMID:
9154970
28.

Polyamine analogue regulation of NMDA MK-801 binding: a structure-activity study.

Bergeron RJ, Weimar WR, Wu Q, Feng Y, McManis JS.

J Med Chem. 1996 Dec 20;39(26):5257-66.

PMID:
8978854
29.

Synthesis and biological evaluation of naphthyldesferrithiocin iron chelators.

Bergeron RJ, Wiegand J, Wollenweber M, McManis JS, Algee SE, Ratliff-Thompson K.

J Med Chem. 1996 Apr 12;39(8):1575-81.

PMID:
8648596
30.

The role of charge in polyamine analogue recognition.

Bergeron RJ, McManis JS, Weimar WR, Schreier KM, Gao F, Wu Q, Ortiz-Ocasio J, Luchetta GR, Porter C, Vinson JR.

J Med Chem. 1995 Jun 23;38(13):2278-85.

PMID:
7608892
31.

Impact of polyamine analogues on the NMDA receptor.

Bergeron RJ, Weimar WR, Wu Q, Austin JK Jr, McManis JS.

J Med Chem. 1995 Feb 3;38(3):425-8.

PMID:
7853334
32.

Design and testing of novel cytotoxic polyamine analogues.

Basu HS, Marton LJ, Pellarin M, Deen DF, McManis JS, Liu CZ, Bergeron RJ, Feuerstein BG.

Cancer Res. 1994 Dec 1;54(23):6210-4.

33.

Antiproliferative properties of polyamine analogues: a structure-activity study.

Bergeron RJ, McManis JS, Liu CZ, Feng Y, Weimar WR, Luchetta GR, Wu Q, Ortiz-Ocasio J, Vinson JR, Kramer D, et al.

J Med Chem. 1994 Oct 14;37(21):3464-76.

PMID:
7932575
34.

The desferrithiocin pharmacophore.

Bergeron RJ, Liu CZ, McManis JS, Xia MX, Algee SE, Wiegand J.

J Med Chem. 1994 May 13;37(10):1411-7.

PMID:
8182699
35.

Structural alterations in desferrioxamine compatible with iron clearance in animals.

Bergeron RJ, Liu ZR, McManis JS, Wiegand J.

J Med Chem. 1992 Dec 11;35(25):4739-44.

PMID:
1469701
36.

Synthesis and biological evaluation of hydroxamate-based iron chelators.

Bergeron RJ, Wiegand J, McManis JS, Perumal PT.

J Med Chem. 1991 Nov;34(11):3182-7.

PMID:
1956036
37.

Synthetic polyamine analogues as antineoplastics.

Bergeron RJ, Neims AH, McManis JS, Hawthorne TR, Vinson JR, Bortell R, Ingeno MJ.

J Med Chem. 1988 Jun;31(6):1183-90.

PMID:
3373487

Supplemental Content

Loading ...
Support Center